tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

DiaMedica Therapeutics price target raised to $12 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $12 from $10 and keeps a Buy rating on the shares. The firm says that with the positive interim results from Part 1a of the Phase 2 study, there is “tangible evidence” for the therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints from the dose escalation.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1